Why Teva Pharmaceuticals Stock Blasted 6% Higher Today
A positive change in recommendation from a well-known bank was the fuel propelling Teva Pharmaceutical Industries's (NYSE: TEVA) well higher on Monday. The company, known for being a top producer of generic drugs, saw its share price swell almost 6% as a result. That was good enough to beat even the very frothy S 500's (SNPINDEX: ^GSPC) 3.3% gain that trading session.
The person behind the modification was JPMorgan Chase analyst Chris Schott, who pushed up his Teva stock recommendation one notch from neutral to overweight (read: buy). He also bumped his price target higher, from $21 per share to $23. The new level anticipates upside of 28% on the most recent closing stock price.
Image source: Getty Images.
Source Fool.com
JPMorgan Chase & Co. Aktie
263,10 €
-0,81 %
Überwältigendes Buy-Interesse bei JPMorgan Chase & Co., mit einer hohen Anzahl von Buy- und wenigen Sell-Einschätzungen.
Die Community prognostiziert für JPMorgan Chase & Co. ein Kursziel von 280 €, was einen leichten Anstieg gegenüber 263.1 € darstellt.
